The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">acute_1</font> <font color="blue">myeloid_1</font> <font color="blue">leukemia_1</font> <font color="blue">and_1</font> <font color="blue">myelodysplastic_1</font> <font color="blue">syndromes_1</font> <font color="blue">:_1</font> <font color="blue">a_1</font> <font color="blue">Japanese_1</font> <font color="blue">multicenter_1</font> <font color="blue">randomized_1</font> <font color="blue">,_1</font> <font color="blue">controlled_1</font> <font color="blue">study_1</font> <font color="blue">._1</font> 
<br>
<br> We performed a <font color="blue">randomized_1</font> <font color="blue">,_1</font> <font color="blue">controlled_1</font> <font color="blue">study_1</font> <font color="blue">comparing_1</font> <font color="blue">the_1</font> <font color="blue">prophylactic_2</font> <font color="blue">effects_2</font> <font color="blue">of_2</font> <font color="blue">capsule_2</font> <font color="blue">forms_2</font> <font color="blue">of_2</font> <font color="blue">fluconazole_2</font> <font color="blue">(_2</font> <font color="blue">n_2</font> <font color="blue">=_2</font> <font color="blue">110_2</font> <font color="blue">)_2</font> <font color="blue">and_2</font> <font color="blue">itraconazole_2</font> <font color="blue">(_2</font> <font color="blue">n_2</font> <font color="blue">=_2</font> <font color="blue">108_2</font> <font color="blue">)_2</font> <font color="blue">in_2</font> <font color="blue">patients_5</font> <font color="blue">with_4</font> <font color="blue">acute_4</font> <font color="blue">myeloid_4</font> <font color="blue">leukemia_4</font> <font color="blue">(_4</font> <font color="blue">AML_4</font> <font color="blue">)_4</font> <font color="blue">or_4</font> <font color="blue">myelodysplastic_4</font> <font color="blue">syndromes_4</font> <font color="blue">(_4</font> <font color="blue">MDS_4</font> <font color="blue">)_4</font> <font color="blue">during_3</font> <font color="blue">and_3</font> <font color="blue">after_3</font> <font color="blue">chemotherapy_3</font> <font color="blue">._3</font> There were <font color="blue">4_1</font> <font color="blue">cases_1</font> with possible systemic fungal infection in the <font color="blue">itraconazole_1</font> <font color="blue">group_1</font> <font color="blue">,_1</font> and there were <font color="blue">8_1</font> <font color="blue">possible_1</font> <font color="blue">and_1</font> <font color="blue">3_1</font> <font color="blue">probable_1</font> cases in the <font color="blue">fluconazole_1</font> <font color="blue">group_1</font> <font color="blue">._1</font> Adverse events did not significantly differ in the <font color="blue">2_1</font> <font color="blue">groups_1</font> <font color="blue">._1</font> In <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">MDS_1</font> or in the remission - induction phase of chemotherapy , the numbers of cases with probable or possible infections were lower in the <font color="blue">itraconazole_1</font> <font color="blue">group_1</font> than in the <font color="blue">fluconazole_1</font> <font color="blue">group_1</font> <font color="blue">,_1</font> whereas no difference was seen in <font color="blue">patients_1</font> with AML or in the consolidation phase of therapy . In <font color="blue">patients_2</font> <font color="blue">with_1</font> <font color="blue">neutrophil_1</font> <font color="blue">counts_1</font> <font color="blue">of_1</font> <font color="blue">>_1</font> <font color="blue">0.1_1</font> <font color="blue">x_1</font> <font color="blue">10(9)/L_1</font> lasting for more than 4 weeks , the frequency of infection in the <font color="blue">fluconazole_1</font> <font color="blue">group_1</font> ( 5 of 9 patients ) was significantly higher than in the <font color="blue">itraconazole_1</font> <font color="blue">group_1</font> ( 0 of 7 patients ; P = .03 ) . Our results suggest that both drugs were well tolerated in <font color="blue">patients_3</font> <font color="blue">with_2</font> <font color="blue">AML_2</font> <font color="blue">or_2</font> <font color="blue">MDS_2</font> <font color="blue">who_2</font> <font color="blue">received_2</font> <font color="blue">chemotherapy_2</font> and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .